TR201905393T4 - Terapötik protein temelli moleküllerin yeni bir sınıfı. - Google Patents

Terapötik protein temelli moleküllerin yeni bir sınıfı. Download PDF

Info

Publication number
TR201905393T4
TR201905393T4 TR2019/05393T TR201905393T TR201905393T4 TR 201905393 T4 TR201905393 T4 TR 201905393T4 TR 2019/05393 T TR2019/05393 T TR 2019/05393T TR 201905393 T TR201905393 T TR 201905393T TR 201905393 T4 TR201905393 T4 TR 201905393T4
Authority
TR
Turkey
Prior art keywords
compositions
methods
present
compounds
infection
Prior art date
Application number
TR2019/05393T
Other languages
English (en)
Inventor
Fang Fang
Malakhov Michael
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of TR201905393T4 publication Critical patent/TR201905393T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mevcut buluş, patojenik enfeksiyonu önlemek ve tedavi etmek için yeni bileşimler ve yöntemler sağlar. Özel olarak, mevcut buluş, bileşiği bir hedef hücrenin yüzeyine ankraj eden bir ankrajlama alanına ve bir hedef hücrenin bir patojen, örneğin, bir virüs, tarafından enfeksiyonunu önlemek için ekstraselüler olarak etki edebilen bir terapötik alana sahip olan bileşikler sağlar. Mevcut buluş ayrıca, siyalidaz aktivitesine sahip olan, siyalidaz katalitik alanlarına sahip olan protein-temelli bileşikleri içeren terapötik bileşimleri de içerir. Buluşun bileşikleri, patojen enfeksiyonunu tedavi etmek veya önlemek için ve alerjik ve enflamatuvar yanıtları tedavi etmek ve azaltmak için kullanılabilir. Buluş ayrıca, hedef hücrelerin rekombinant virüsler tarafından transdüksiyonunu arttırmak için bileşimler ve yöntemler de sağlar. Bu tarz bileşimler ve yöntemler gen terapisinde kullanılabilir.
TR2019/05393T 2004-09-10 2005-07-21 Terapötik protein temelli moleküllerin yeni bir sınıfı. TR201905393T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/939,262 US7807174B2 (en) 2002-11-22 2004-09-10 Class of therapeutic protein based molecules

Publications (1)

Publication Number Publication Date
TR201905393T4 true TR201905393T4 (tr) 2019-05-21

Family

ID=36060467

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05393T TR201905393T4 (tr) 2004-09-10 2005-07-21 Terapötik protein temelli moleküllerin yeni bir sınıfı.

Country Status (17)

Country Link
US (2) US7807174B2 (tr)
EP (4) EP3530734A1 (tr)
JP (2) JP4764881B2 (tr)
KR (1) KR20070064619A (tr)
CN (2) CN101426906B (tr)
AU (1) AU2005285461B2 (tr)
BR (1) BRPI0515646B8 (tr)
CA (2) CA2578050C (tr)
DK (3) DK3241898T3 (tr)
ES (3) ES2626845T3 (tr)
HK (2) HK1201562A1 (tr)
IL (3) IL181779A (tr)
PT (3) PT1786902E (tr)
RU (1) RU2468080C2 (tr)
TR (1) TR201905393T4 (tr)
WO (1) WO2006031291A2 (tr)
ZA (1) ZA200702915B (tr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
EP1567185B1 (en) * 2002-11-22 2020-02-19 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
MY143242A (en) * 2004-11-10 2011-04-15 Hitachi Chemical Co Ltd Metal foil provided with adhesion auxiliary material and printed wiring board using same
AU2006307458A1 (en) * 2005-10-25 2007-05-03 Mnd Diagnostic Ltd. Compositions for- detecting of influenza viruses and kits and methods using same
KR101501780B1 (ko) 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
AU2013237761B8 (en) * 2006-01-24 2015-06-04 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
AU2015215955B2 (en) * 2006-01-24 2016-12-01 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
US8273381B1 (en) * 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
US20100143972A1 (en) * 2006-12-14 2010-06-10 Horswill Alexander R Method of Making Cyclic Polypeptides with Inteins
PL2113027T3 (pl) * 2007-02-20 2014-11-28 Dsm Ip Assets Bv Nowa sialidaza
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
SG176045A1 (en) 2009-05-12 2011-12-29 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
US9023877B2 (en) * 2009-06-26 2015-05-05 Romark Laboratories L.C. Compounds and methods for treating influenza
BR112012002163A2 (pt) * 2009-07-31 2015-11-03 Danisco Us Inc proteases com regiões pré-pró modificadas
US8398971B2 (en) * 2009-11-06 2013-03-19 Nexbio, Inc. Methods, compounds, and compositions for treatment and prophylaxis in the respiratory tract
CA2864746A1 (en) * 2012-02-17 2013-08-22 Ansun Biopharma, Inc. Methods, compounds and compositions for treatment of influenza and parainfluenza patients
US20140154308A1 (en) * 2012-06-28 2014-06-05 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
CA3185756A1 (en) 2012-12-24 2014-07-03 Coagulant Therapeutics Corporation Short-acting factor vii polypeptides
AU2014239573B2 (en) * 2013-03-15 2019-11-21 Ansun Biopharma, Inc. Novel method of protein purification
US20160101161A1 (en) * 2013-06-03 2016-04-14 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye
US10300116B2 (en) 2013-06-10 2019-05-28 Ansun Biopharma, Inc. Treatment for BK polyomavirus infection
US20160120961A1 (en) * 2013-06-10 2016-05-05 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
US20170119859A1 (en) 2014-05-30 2017-05-04 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
US10328128B2 (en) 2014-09-17 2019-06-25 Ansun Biopharma, Inc. Treatment of infection by human enterovirus D68
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
US10874749B2 (en) 2015-07-21 2020-12-29 Thomas Jefferson University Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
KR102581747B1 (ko) 2016-07-01 2023-09-22 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 표적 세포 표면 편집을 위한 접합체
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102608876B1 (ko) * 2017-05-26 2023-11-30 게노비스 에이비 글리칸 분석을 위한 효소
CN111051500A (zh) * 2017-09-05 2020-04-21 角斗士生物科学公司 有效载荷递送至干细胞
CN112135904A (zh) 2018-01-03 2020-12-25 帕利昂制药有限公司 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201803197D0 (en) 2018-02-27 2018-04-11 Pneumagen Ltd Viral treatment
CN109991649B (zh) * 2019-03-26 2021-04-06 华中科技大学 一种制备无机闪烁体膜的方法
JP7343890B2 (ja) * 2019-04-26 2023-09-13 国立大学法人東海国立大学機構 シアリダーゼ活性を有する酵素剤及びその利用
CN110038122A (zh) * 2019-05-23 2019-07-23 武汉真福医药股份有限公司 枯草杆菌纤溶酶在治疗支气管炎药物中的应用
MX2021016040A (es) 2019-07-03 2022-03-11 Aillis Inc Composicion farmaceutica para el tratamiento de infecciones de virus de influenza.
CN111450236B (zh) * 2020-02-25 2023-04-07 西北大学 一种用于阻断冠状病毒感染的制剂
WO2021217053A1 (en) * 2020-04-24 2021-10-28 Rezolute, Inc. Plasma kallikrein inhibitors for the treatment of ards and related conditions
US20230218794A1 (en) * 2020-06-10 2023-07-13 The Penn State Research Foundation Process and system to lessen human coronavirus transmission and spread
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
EP4351604A1 (en) * 2021-06-09 2024-04-17 Microbial Machines, Inc. Engineered microorganisms for detection of diseased cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) * 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
AU626521B2 (en) * 1987-03-10 1992-08-06 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5985859A (en) 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
DE69527924T2 (de) * 1994-06-14 2003-01-09 Genencor Int Hitzebeständige xylanasen
CN1185223C (zh) * 1995-02-27 2005-01-19 吉里德科学公司 新颖化合物,其合成方法及治疗用途
GB9513683D0 (en) * 1995-07-05 1995-09-06 Ciba Geigy Ag Products
AU5546898A (en) 1997-01-14 1998-08-07 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) * 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) * 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
CN1405562A (zh) * 2002-10-24 2003-03-26 肖洪武 一种唾液酸酶测定试剂
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
EP1567185B1 (en) * 2002-11-22 2020-02-19 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
DE10258400A1 (de) * 2002-12-13 2004-06-24 N.V. Nutricia Trans-Sialidasen aus Trypanosoma congolense
KR101501780B1 (ko) * 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술

Also Published As

Publication number Publication date
HK1201562A1 (en) 2015-09-04
JP2010279366A (ja) 2010-12-16
ES2721172T3 (es) 2019-07-29
JP2008512117A (ja) 2008-04-24
EP1786902B1 (en) 2015-09-09
RU2468080C2 (ru) 2012-11-27
CA2823429A1 (en) 2006-03-23
BRPI0515646B1 (pt) 2020-10-13
EP3018204A1 (en) 2016-05-11
EP3241898B1 (en) 2019-01-23
EP1786902A4 (en) 2009-12-09
AU2005285461A1 (en) 2006-03-23
DK3018204T3 (en) 2017-07-31
CA2823429C (en) 2019-06-04
IL241227A0 (en) 2015-11-30
IL181779A (en) 2015-10-29
BRPI0515646A8 (pt) 2017-04-04
IL207957A0 (en) 2010-12-30
CN104017787B (zh) 2017-03-29
PT3018204T (pt) 2017-07-13
WO2006031291A3 (en) 2009-04-16
US20090142327A1 (en) 2009-06-04
US20050112751A1 (en) 2005-05-26
IL241227B (en) 2020-05-31
CN101426906B (zh) 2013-06-26
AU2005285461B2 (en) 2011-03-03
KR20070064619A (ko) 2007-06-21
EP3018204B1 (en) 2017-04-12
BRPI0515646B8 (pt) 2021-05-25
JP4764881B2 (ja) 2011-09-07
HK1224329A1 (zh) 2017-08-18
EP3530734A1 (en) 2019-08-28
US7807174B2 (en) 2010-10-05
CN104017787A (zh) 2014-09-03
ES2554787T3 (es) 2015-12-23
IL207957A (en) 2016-10-31
CA2578050A1 (en) 2006-03-23
CN101426906A (zh) 2009-05-06
IL181779A0 (en) 2007-07-04
US7645448B2 (en) 2010-01-12
RU2007112502A (ru) 2008-10-20
DK3241898T3 (en) 2019-04-29
CA2578050C (en) 2015-04-21
ES2626845T3 (es) 2017-07-26
EP3241898A1 (en) 2017-11-08
DK1786902T3 (en) 2015-10-19
PT1786902E (pt) 2015-12-22
JP5307082B2 (ja) 2013-10-02
WO2006031291A2 (en) 2006-03-23
BRPI0515646A (pt) 2008-07-15
EP1786902A2 (en) 2007-05-23
PT3241898T (pt) 2019-05-20
ZA200702915B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
TR201905393T4 (tr) Terapötik protein temelli moleküllerin yeni bir sınıfı.
Baker-Williams et al. Co-chaperones TIMP2 and AHA1 competitively regulate extracellular HSP90: client MMP2 activity and matrix proteolysis
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE251942T1 (de) Stapelbare statische mischelemente
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
MA34209B1 (fr) Protéines à domaine de squelette basé sur la fibronectine qui se lient à pcsk9
EA201300867A1 (ru) ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
EA200870164A1 (ru) Лечение вирусного гепатита
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
BRPI0721137B8 (pt) compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos.
NO20061194L (no) Mitotiske kinesininbibitorer
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE460923T1 (de) Lyophilisierung von virosomen
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
ATE471326T1 (de) Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon